Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company ...

Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly's stock isn't cheap The company's stock trades at a hefty 39 times forward earnings. That's very high for a pharma company and more than twice its main GLP-1 competitor, Novo Nordisk.

Eli Lilly and Company (NYSE:LLY) is one of the Top 10 Stocks Wall Street is Buzzing About These Days. Talking about Morgan Stanley’s bullish call on Eli Lilly and Company (NYSE:LLY), Kevin Simpson, ...

Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance Eli Lilly sees FY24 EPS $12.20-$12.70, consensus $12.43 Eli Lilly reports Q4 EPS $2.49, consensus $2.19 ...

Shares of Eli Lilly and Company (NYSE: LLY) skyrocketed 59% in 2023. The big drugmaker delivered its second-best stock performance in the last 25 years, eclipsed only by a gain of nearly 64% in 2021.

Eli Lilly (NYSE:LLY) is scheduled to release its earnings report on Thursday, May 1, 2025. For event-driven traders, historical stock performance following earnings announcements may offer ...